ARGX
Argenx SE
A biopharmaceutical company that develops antibody-based medicines for severe autoimmune diseases, best known for Vyvgart, an FDA-approved treatment for generalized myasthenia gravis. Founded in 2008 in Ghent, Belgium, by three scientists, the company is incorporated in the Netherlands. Its name comes from the Argonauts of Greek myth, chosen to celebrate teamwork over the lone hero.
ADRUnderlying: ARGXCUSIP: 04016X101HealthcareNL1 holder
Sponsored American Depositary Receipt (ADR) representing ordinary shares of argenx SE